Azintuxizumab vedotin

Names

[ CAS No. ]:
1826819-58-2

[ Name ]:
Azintuxizumab vedotin

Biological Activity

[Description]:

Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells[1].

[Related Catalog]:

Research Areas >> Cancer

[Target]

CD2 subset 1[1]


[In Vitro]

Azintuxizumab vedotin (ABBV-838) 是一种 ADC，由人源化重组免疫球蛋白 G1κ 组成，针对 CD2 subset 1 (CS1，也称为 SLAMF7) 的独特表位，通过缬氨酸-瓜氨酸连接子与细胞毒性单甲基 auristatin E (MMAE) 结合[1]。 Azintuxizumab vedotin 对表达 CS1 的癌细胞显示出强大的细胞毒活性[1]。

[In Vivo]

Azintuxizumab vedotin (ABBV-838) 在使用人骨髓瘤异种移植的小鼠模型中显示单药抗肿瘤活性[1]。

[References]

[1]. Vij R, et al. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 May 15;26(10):2308-2317.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.